Please login to the form below
Sarepta
This page shows the latest Sarepta news and features for those working in and with pharma, biotech and healthcare.
Sarepta Therapeutics’ DMD gene therapy shows early success
Sarepta Therapeutics has revealed some early promising data for its Duchenne muscular dystrophy (DMD), although the company also reported serious adverse events associated with the treatment. ... Although Sarepta did not identify any new safety signals
Latest news
-
Lilly links up with Precision BioSciences in genome editing deal
Sarepta is also prominent in the DMD therapy area and the company's second approved DMD therapy Vyondys 53 (golodirsen) received approval last December. ... Vyondys 53 is Sarepta’s second approved DMD therapy after Exondys 51 (eteplirsen).
-
Roche to collaborate with Dyno on gene therapies for CNS/liver diseases
The Roche deal is Dyno’s third pharma collaboration, in addition to its existing partnerships with Novartis and Sarepta Therapeutics. ... disease. The Sarepta deal is focused on the development of new AAV vectors for gene therapies aimed at targeting
-
FDA approves Sarepta rival NS Pharma’s Duchenne drug
The approval will see Viltepso enter a competitive market and likely head into a rivalry with Sarepta’s Vyondys 53 (golodirsen), which gained FDA approval last December.. ... Like NS Pharma, Sarepta is conducting a confirmatory trial of Vyondys 53
-
FDA sets Q3 decision date for NS Pharma’s DMD drug
If approved it will become second-to-market after Sarepta. The US Food and Drug Administration (FDA) has accepted NS Pharma’s application for its Duchenne Muscular Dystrophy (DMD) drug viltolarsen, ... NS Pharma’s drug is designed to treat DMD
-
Solid Bio axes staff by one-third as it clings to troubled DMD programme
Sarepta Therapeutics was granted a surprise FDA approval for its follow-up DMD drug Vyondys 53 – a drug which was also plagued with safety concerns and was initially rejected by the
More from news
Approximately 19 fully matching, plus 27 partially matching documents found.
Latest Intelligence
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
including Shire/Takeda, Actelion/J&J, Sanofi Genzyme, Alexion, Amicus, BioMarin, Sarepta and Vertex.
-
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Alnylam can take heart in exceptions, however, such as Sarepta, with its Duchenne treatment Exondys 51, and hope it too can buck this trend.
-
Bluebird Bio: on the cusp of a gene therapy revolution
A gene therapy, and Duchenne pioneer Sarepta.
-
Deal Watch February 2017
Licence. 145. Sarepta Therapeutics/ Gilead Sciences. PRV received when EXONDYS 51 was FDA approved for Duchenne muscular dystrophy.
-
Deal Watch October 2016
The licence deal obtained by Summit from Sarepta for a phase II product had an even lower upfront, 7% of the total consideration. ... 767. Sarepta (US). Summit (UK). Licence collaboration. Europe Utrophin modulator pipeline, lead molecule phase II for
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest appointments
-
New hires at bluebird bio, BioNTech and Provention Bio
He has also held sales, marketing and medical affairs leadership roles at Sarepta Therapeutics, Vertex Pharmaceuticals and Gilead Sciences.
-
Minoryx Therapeutics adds to board of directors
He brings over 30 years of regulatory strategy expertise to the orphan diseases specialist, and currently also serves as a board member at Sarepta Therapeutics.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
W2O Group
Sanofi. Bayer. Sarepta Therapeutics.
W2O Group
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
-
B2B media account director
-
Competitive salary
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- AM / Senior Account Manager – Healthcare PR - London / Remote
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- FREELANCE Associate Director - Healthcare PR - Remote or London
-
Superb Day Rate &Benefits
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Omicron rise prompts tougher measures in England
- Pfizer/BioNTech promote booster against Omicron
- What is EVID AI?
- Virtual meeting technologies for reducing emissions and waste in the healthcare industry
- AstraZeneca and Ionis sign $3.6bn deal for eplontersen
- Roche’s Actemra approved for severe COVID-19 in Europe
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Sanofi to buy acne specialist Origimm
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- Promoting off-label use: where to draw the line?
- Synairgen’s SNG001 advances into phase 3 COVID-19 trial
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
PMHub
Lucid Group Communications Limited
WE’RE ON A MISSION
To transform lives through communication that changes behaviour and improves health outcomes....
Latest intelligence
- Virtual meeting technologies for reducing emissions and waste in the healthcare industry
- ...
- Diversity in clinical trials: looking back at our 2021 blogs
- In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
